You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Caplin Point subsidiary gets approval from Brazil's ANVISA

Capital Market 

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received approval from Brazil's National Health Surveillance Agency ANVISA for its sterile injectable manufacturing site near Chennai, Tamilnadu.

The approval grants access to the company to register and market its products in Brazil, the largest Pharmaceutical market in Latin America.

C. C. Paarthipan, chairman of Caplin Point Laboratories commented Brazil is an important target for Caplin Steriles' mid to long term expansion plans. As a first step, we will focus on extending our US approved products for Brazil.

The National Health Surveillance Agency or ANVISA (Agcia Nacional de Vigilcia Sanitia) is the Brazilian regulatory agency that is responsible for the approval and supervision of food, cosmetics, tobacco, pharmaceuticals, health services, and medical devices, among others. The agency is connected to the Ministry of Health, which manages ANVISA through a management contract signed periodically.

Caplin Steriles is a niche sterile product manufacturing company that is approved by USFDA and EU-GMP. Caplin Steriles has developed and filed 20 ANDAs in USA on its own and with partners, with 16 approvals so far. The company is also working on a portfolio of around 45 simple and complex injectable and ophthalmic products, that it intends to file over the next 4 years.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. On a consolidated basis, the company's net profit increased by nearly 30% to Rs 70.85 crore on a 25.1% rise in net sales to Rs 300.44 crore in Q1 FY22 over Q1 FY21.

Shares of Caplin Point were trading 1.73% lower at Rs 807.15 on BSE.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, August 17 2021. 13:40 IST